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acute GVHD (p¼0.71). Only BKV subtype III had a statistically
signiﬁcant correlation with HC (OR: 10.8, 95%CI: 1.64-70.93,
p¼0.013).
Conclusion: BKV is ubiquitous among humans, infecting
children asymptomatically and then persisting in renal
tissue. Subtype Ic is most prevalent (>90%), followed by
subtype IV, while subtype III are rarely found in Japan. Our
data suggested the importance of BKV subtype III in the
development of BKV-HC. Further studies focused on the viral
genomic variation in the pathogenesis of BKV-HC are
warranted.
Figure 1.
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Background: Allogeneic hematopoietic cell transplantation
(alloHCT) is the only option for cure for many patients with
hematological malignancies such as leukemia and MDS;
however many patients, especially the older population,
cannot tolerate full-intensity ablative conditioning regimens.
Fludarabine and melphalan has been efﬁcacious as a reduced
intensity conditioning regimen for alloHCT for multiple
malignancies, but the relapse rate for this regimen remains
high. We have replaced ﬂudarabine with clofarabine,
a rationally designed second-generation purine nucleoside
analog. Clofarabine has increased immunosuppressive and
anti-leukemic activity compared to ﬂudarabine in vitro, and
we have found in a phase I study that the clofarabine/
melphalan conditioning regimen for alloHCT in patients with
acute leukemia or MDS is safe and tolerable. We hypothe-
sized that analysis of outcomes for patients treated using thisregimen would demonstrate favorable relapse rates while
maintaining a low-toxicity proﬁle.
Patients & Methods: Twenty patients with high-risk
leukemia or MDS, with a median age of 63 years, underwent
alloHCT from November 2007 until June of 2012. Patients
were treated at one of three dose levels of a clofarabine (day
-9 to day -5) and melphalan (on day -4) conditioning
regimen: 3 patients received 30 mg/m2 clofarabine and 100
mg/m2 melphalan (dose level 1), 12 patients received 40 mg/
m2 clofarabine and 100mg/m2melphalan (dose level 2), and
5 patients received 40 mg/m2 clofarabine and 140 mg/ m2
melphalan (dose level 3). The ﬁrst 16 patients were included
in a phase 1 prospective study and 4 additional patients were
treated at dose level 3 off protocol. Graft-versus-host-disease
(GVHD) prophylaxis began on day -3with the combination of
tacrolimus and sirolimus.
Results: The median follow-up for surviving patients was
28.7months (1.1 - 52.9). Overall survival at 1 year and 2 years
was 77% and 70 % respectively. Event-free survival at 1 and 2
years was the same, at 70.7% (95% CI: 52.1 - 83.2). Fifty
percent of patients experienced acute GVHD (grades I and II
only), and 69% of evaluable patients experienced chronic
GVHD. The majority of toxicities were related to the gastro-
intestinal system including elevated liver enzymes with one
patient experiencing grade 4 hepatic toxicity. Other adverse
events included renal insufﬁciency (5 patients), CNS toxicity
(2 patients), and cardiac toxicity (1 patient).
Conclusion: The combination of clofarabine and high dose
melphalan is a well tolerated conditioning regimen that
provides a durable remission and event-free survival of 70.7%
in patients with high-risk disease. We are planning to initiate
a phase 2 trial to examine the anti-leukemic activity of dose
level 3 for this clofarabine/melphalan reduced-intensity
alloHCT regimen in patients with high-risk acute myeloge-
nous leukemia.
Overall Survival and Event Free Survival Patients treated with Clo/Mel at 30/
100 (n¼3), 40/100 (n¼12), 40/140 (n¼5) Transplant Date Range: 11/28/2007-
06/28/2012.
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Platelet engraftment failure is a serious complication
leading to poor overall survival and quality of life in stem cell
transplantation. Neutrophil engraftment failure is usually
associated with failure of platelet engraftment. Relapse of
underlying disease such as acute leukemia can delay platelet
recovery. Because both of these situations aremajor causes of
poor survival, effect of platelet engraftment on survival is not
obvious in patients after neutrophil engraftment without
relapse.
We analyzed platelet engraftment in unrelated BMT (UR-
BMT), related BMT (Rel-BMT), related PBSCT (Rel-PBSCT),
and CBT using transplant outcome database of Japan Society
for Hematopoietic Cell Transplantation. Platelet engraftment
was deﬁned by the ﬁrst of three successive days with a non-
transfused platelet count of greater than 20x109/L. We
excluded cases with neutrophil engraftment failure or
relapse before achieving platelet engraftment, because both
of them can cause delay of platelet recovery. The study
population consisted of 12,101 patients who underwent UR-
BMT (3,482), Rel-BMT (3,153), Rel-PBSCT (2,834), or CBT
(2,632) for AML, ALL, CML, and MDS. The percentage of
platelet recovery (platelet count > 20x109/L, without trans-
fusion) in UR-BMT, Rel-BMT, Rel-PBSCT, and CBT was 89%,
94%, 93%, and 84%, and the median days of recovery after
transplantation was 28, 24, 18, and 44 days, respectively.
Multivariate Cox proportional hazards regression analysis
revealed that advanced stage of disease and poor perfor-
mance status ( grade 2) were common risk factors for
platelet engraftment failure in the four donor sources. Lower
cell dose was a signiﬁcant risk factor in UR-BMT and CBT.
HLA-mismatched graft was also signiﬁcant in the trans-
plantation other than CBT. We analyzed 1 year overall
survival in patients alive with or without platelet engraft-
ment every 10 days from 20 days to 100 days after trans-
plantation. Patients without platelet recovery showed
signiﬁcant poor survival than those with the recovery (Log-
rank test, p<0.001) at every point except day 20 in CBT. The
estimated 1 year overall survival of patients alive at day 100
with or without platelet recovery is 79% vs 62% (UR-BMT),
81% vs 62% (Rel-BMT), 72% vs 57% (Rel-PBSCT), 77% vs 57%
(CBT), and the probability of eventually achieving platelet
count>20x109/L in patients without recovery at day 100 was
25%, 31%, 34%, and 44%, respectively. Multivariate analysis
conﬁrmed that platelet recovery was signiﬁcantly associated
with survival.
In conclusion, platelet engraftment predicted overall
survival even excluding neutrophil engraftment failure and
early relapse in BMT, related PBSCT, and CBT.23
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We compared overall survival for recipients of a single
UCB unit treated for hematological malignancy on the COBLT
Study (n¼191) conducted from 1999-2004 to BMT CTN 0501
(n¼113) conducted from 2006-2012. The BMT CTN 0501 is
sponsored by NHLBI and NCI and, COBLT was sponsored by
NHLBI. Overall survival at 1-year was the primary endpoint
for both trials. Eligibility for both trials was similar with
a minimum total nucleated cell dose (TNC) of 2.5x107/kg for
BMT CTN and 1x107/kg for COBLT and HLA match of 4/6 at
antigen level for HLA A and B and allele level for HLA DRB1.
All patients received TBI 1350 cGy and cyclophosphamide
120 mg/kg. Patients enrolled on COBLT also received equine
ATG 90 mg/kg and those on BMT CTN 0501 ﬂudarabine
75mg/m2 with GVHD prophylaxis consisting of cyclosporine/
methyl prednisone and cyclosporine/mycophenolatemofetil,
respectively. The distribution of patient performance scores,
diseases, TNC (median dose: 4.8 x 107/kg for BMT CTN 0501
and COBLT, 5. 1 x 107/kg) and CD34 dose of the UCB units
were similar. Compared to those on BMT CTN 0501, patients
on COBLT were slightly younger (median age: 8 vs. 10 years,
p¼0.0007), more likely to be in relapse at transplant (16% vs.
5%, p¼0.0002) and less likely to receive a 5-6/6 HLA-matched
unit (29% vs. 59%, p<0.0001). The 1-year, the probabilities of
overall survival were 57% (95% CI 50 e 64) on COBLT and 71%
(95% CI 62 e 79) on BMT CTN 0501 (p¼0.01). In multivariate
analysis, mortality risks were higher for patients enrolled on
COBLT compared to those on BMT CTN 0501 (HR 1.82, 95% CI
1.19 e 2.78, p¼0.006). Mortality risks were also higher in
non-Caucasians independent of clinical trial (HR 1.95, 95%
1.32 e 2.88, p¼0.0007). The primary causes of death on both
trials were similar except for higher incidence of primary
graft failure on COBLT. The most frequent causes of death in
both treatment groups were recurrent leukemia and GVHD.
In summary, survival was better for patients treated on BMT
CTN 0501. Although it is not possible to prove which factor(s)
played the greatest role, it is the “package” including
conditioning and GVHD prophylactic regimens, supportive
care, method of unit selection and transplantation period
combined that contributed to the improved survival
observed in recipients of a single UCB unit in BMT CTN 0501.
Together, these results suggest the BMT CTN 0501 treatment
plan represents the new standard by which treatment
modiﬁcations will be compared.24
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